W hole blood is an attractive sample source for nucleic acid-based assays because it is readily available, easily accessible, and rich in genetic information. However, globin mRNA accounts for up to 70% of the mRNA (by mass) in whole blood total RNA, resulting in distortion of the RNA amplification and subsequently causing decreased Present calls, decreased call concordance, and increased signal variation in microarray analysis. Therefore, for gene expression analysis, whole blood is typically fractionated before total RNA isolation to reduce globin mRNA content. We have developed a high-throughput sample preparation technology that streamlines workflows for (1) total RNA isolation from whole blood (MagMAX-96 Blood RNA Isolation Kit), (2) globin mRNA removal using a novel, nonenzymatic technology (GLOBINcleardHuman Kit), and (3) mRNA amplification and labeling for expression analysis (MessageAmp II-96 aRNA Amplification Kit). Globin mRNA removal eliminates the need for prefractionation of whole blood, minimizing the potential for expression profile changes during sample handling. Quantitative RT-PCR showed that this method effectively removed up to 95% of the globin mRNA from the isolated RNA while retaining normal levels of other mRNAs. The streamlined sample preparation enables quick and accurate expression analysis of relatively high numbers of blood samples. ( JALA 2006;11:381-6) Xingwang Fang, Ph.D.
INTRODUCTION
In recent years, gene expression profiling, by means of microarrays, has become a powerful, frequently used tool for studying human diseases and their responses to drug therapies. 1 The emergence of pharmacogenomic and personalized medicine in the near future is projected to increase demand for use of this technology. Whole blood is an ideal sample source for gene expression profiling because it is readily available, easily accessible, and rich in genetic information. 2 A robust, automatable process for preparing RNA from whole blood is needed to enable high-volume studies.
Most useful genetic information in whole blood resides primarily in the peripheral blood mononuclear cells, which make up approximately 0.1% of the blood cellular fraction. Globin mRNA from reticulocytes accounts for up to 70% (by mass) of the total mRNA in the whole blood. When total RNA from whole blood is amplified using the Eberwine linear amplification procedure, 3 globin mRNA product dominates the amplified RNA (aRNA). This has been shown to decrease Present calls and call concordance, and to increase signal variation. 2,4e6 For this reason, blood is typically fractionated before total RNA isolation. However, fractionation increases sample handling, which can lead to RNA degradation and expression profile changes. Also, blood fractionation is very difficult to automate or to scale up for high-throughput processing because centrifugation is typically used in blood fractionation procedures. For these reasons, an increasing trend is to isolate total RNA from whole blood, followed by globin mRNA reduction before amplification.
A typical approach for globin mRNA reduction is targeted degradation of globin mRNA by hybridization of total RNA with oligonucleotides complementary to globin mRNA and digestion of the mRNA/DNA hybrids with RNase H. 5 This approach has been shown to significantly increase the Present calls on GeneChip arrays with some change in call concordance, 5 probably due to degradation of RNA during the treatment.
A novel, nonenzymatic globin mRNA reduction method (GLOBINclear Kits) has been developed at Ambion. 7 Biotin-labeled oligonucleotides complementary to multiple regions of both aand b-globin mRNA are hybridized with total RNA, and the biotin-labeled oligonucleotideeglobin mRNA hybrids are then removed with magnetic streptavidin beads. This approach efficiently removes both aand bglobin mRNA while keeping other mRNAs intact.
We have developed a magnetic bead-based high-throughput total RNA isolation protocol from whole blood (Mag-MAX-96 Blood RNA Isolation Kit), which provides a streamlined magnetic bead-based workflow for RNA isolation from whole blood. We describe here the integration of three products in a semi-automated process for (1) sample preparation from whole blood (MagMAX-96 Blood RNA Isolation Kit), (2) globin mRNA removal (GLOBINcleard Human Kit), and (3) RNA amplification, labeling, and purification (MessageAmp II-96 aRNA Amplification Kit), all in a 96-well format. This streamlined workflow enables highthroughput expression analysis using whole blood samples.
MATERIALS AND METHODS

Blood Collection
Whole blood (10 ml) was collected from two human donors in EDTA-containing Vacutainer tubes (BD). For each donor sample, 300 mL aliquots were distributed to 24 wells of a 96-well plate containing 600 mL lysis/binding Solution. The blood was stored briefly (!10 min) in the collection tubes at room temperature until addition to lysis plate, described below.
RNA Isolation and Analysis
The MagMAX-96 Blood RNA Isolation Kit protocol was modified to accommodate 300 mL whole blood samples, and implemented on the KingFisher 96 Magnetic Particle Processor (Thermo Electron Corp.). The reagent volumes and layout of the KingFisher 96 Processor turntable are listed in Figure 1 . The lysis plate was prepared immediately before starting the process to minimize RNA degradation. The KingFisher 96 Processor completed the lysing, washing, genomic DNA digestion, and final RNA purification in !1 h.
RNA yield was quantified by A 260 using a UVeVis spectrophotometer (NanoDrop Technologies), and its integrity was examined by microfluidics capillary electrophoresis with an RNA LabChip Kit on an Agilent 2100 bioanalyzer.
Quantitative RT-PCR (qRT-PCR) targeting PTGS2 and TP53 was performed on a 7900HT Fast Real-Time PCR System using appropriate TaqMan Gene Expression Assays (Applied Biosystems Inc.). An internal control transcript, XenoRNA-01 Control RNA was used to monitor efficiency of qRT-PCR reactions. XenoRNA-01 Control RNA is 1 kb long, and shows no sequence homology to any sequence deposited at GenBank.
High-Throughput Globin mRNA Removal
Globin mRNA removal was performed with 0.3e1 mg total RNA samples in triplicate using a GLOBINcleard Human Kit (Ambion Inc.) following the standard protocol from the instruction manual. 7 The process was implemented on a Biomek NX Laboratory Automation Workstation (Beckman Coulter) equipped with an MJ Moto Alpha Thermocycler (MJ Research) and a 96-Well Magnetic-Ring Stand (Ambion). The initial 50 C incubation steps were performed in a 96-well PCR plate (Applied Biosystems), and all subsequent steps were performed in a 96-well U-bottom plate. qRT-PCR was used to measure globin mRNA before and after the procedure, normalized to human RNA polymerase II (hRPII) mRNA, to calculate the efficiency of globin mRNA removal.
mRNA Amplification and Biotin Labeling
Globin-depleted total RNA was amplified and labeled using a MessageAmp II-96 aRNA Amplification Kit (Ambion), which is based on the Eberwine procedure. 7 Briefly, total RNA is reverse transcribed using an oligo(dT) primer bearing a T7 promoter sequence. The cDNA undergoes second-strand synthesis and purification to yield a template for in vitro transcription (amplification) with T7 RNA polymerase. Biotin-11-Uridine-5 2 -triphosphate (Biotin-UTP) was used in the transcription reaction to label the aRNA. Magnetic bead-based methods for both cDNA and aRNA purification 8 were implemented on a Biomek Liquid Handler (Beckman Coulter). The fully automated procedure has been described elsewhere. 9, 10 Microarray Analysis Microarray analysis was performed using GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix), following the standard protocol recommended by the manufacturer, and expression profiles were analyzed with the manufacturer's standard software.
RESULTS AND DISCUSSION
Total RNA Isolation and Quality Examination
Endogenous ribonucleases are abundant in whole blood and can quickly degrade RNA, especially upon cell lysis, 11 if not effectively eliminated. The MagMAX-96 Blood RNA Isolation Kit uses guanidine thiocyanate to lyse blood cells and to denature nucleases 12 while allowing RNA to bind to magnetic beads. Genomic DNA is digested with TURBO DNase under high salt conditions to minimize RNA degradation. For high-throughput preparation of total RNA, magnetic bead-based technology offers the following advantages over glass fiber filter-based methods: (1) the beads can be fully suspended in solution, enabling efficient binding, washing and elution with reduced carryover of inhibitors 10, 13 ; (2) the use of microsized beads permits elution volumes as low as 20 mL, resulting in higher final RNA concentrations that are better suited for downstream processes; and (3) it is more reliable for walk-away automation because there is no potential for vacuum failure or clogging seen in filter-based technology.
The MagMAX-96 Blood RNA Isolation Kit is designed for isolation of total RNA from 50 mL whole blood in a regular 96-well plate, with a typical yield of w0.5 mg total RNA. To obtain enough high-quality RNA for microarray analysis, we scaled up the MagMAX-96 protocol to 300 mL whole blood. In addition, we implemented processing on a KingFisher 96 Magnetic Particle Processor. As determined by A 260 , 1.88 AE 0.29 mg and 2.06 AE 0.28 mg of total RNA were isolated from 300 mL blood samples from Donor 1 and Donor 2, respectively (24 replicates each). Variation in RNA yield between donors is common, mainly due to the difference in white blood cell counts among individuals. The consistency of the RNA yield from donor replicates indicates that the RNA isolation process is robust.
To further illustrate the consistency of RNA yields using the scaled-up MagMAX-96 Blood protocol, eight technical replicates of RNA from each donor were randomly selected and qRT-PCR was performed targeting two volatile blood genes (PTGS2 and TP53; Fig. 2 ). While donor-to-donor variation was significant, as expected, variation among the technical replicates was very low (SD % 0.27C t ) showing that this method is consistent and viable for isolating RNA for gene expression analysis.
The standard GLOBINclear globin mRNA reduction protocol is suitable for RNA samples up to 14 mL. Using MagMAX-96 Blood elution volumes of 50 mL, R0.5 mg total RNA could be used as input for the GLOBINclear protocol without a need for vacuum concentration, allowing the two procedures to be seamlessly linked.
The purity of total RNA isolated from whole blood is a big concern, because whole blood is very rich in proteins, which inhibit reverse transcription. 14, 15 To detect the presence of inhibitors in the RNA isolated using the scaled-up MagMAX-96 Blood protocol, we added 0, 2, and 5 mL of the extracted RNA to 15 mL qRT-PCR control reactions that each contained 1000 molecules of a target XenoRNA-01 Control RNA. As shown in Figure 3 , amplification of XenoRNA-01 Control RNA was not inhibited by as much as 5 mL extracted RNA (1/3 of the total qRT-PCR reaction volume), demonstrating that inhibitors of qRT-PCR reactions were effectively excluded from the recovered RNA.
Because whole blood is rich in nucleases, total RNA isolated from whole blood is often degraded and not suitable for microarray analysis. We examined the integrity of isolated RNA on an Agilent 2100 Bioanalyzer. Twelve samples randomly selected from a 96-well plate had 28S:18S rRNA ratios R1.1 (Fig. 4A and B) ; a ratio of O1.0 is typically considered indicative of RNA with a high degree of integrity for total RNA isolated from whole blood. The RNA Integrity Number (RIN) algorithm analyzes bioanalyzer information from both rRNA bands, as well as information contained outside the rRNA peaks (i.e., potential degradation products), to provide a more complete picture of RNA degradation states. The RIN values for these samples were R6.7 (Fig. 4B) , generally considered to indicate a high degree of integrity. The A 260 /A 280 ratio for all 12 samples was O1.74 ( Fig. 4B) , indicating RNA free of contaminating proteins. These measurements suggest that the scaled-up MagMAX-96 Blood protocol delivered RNA sufficiently intact and pure for high-quality microarray analysis.
Effectiveness of Globin mRNA Reduction
Total RNA isolated from whole blood is very rich in aand b-globin mRNA. A good globin mRNA reduction protocol should effectively remove both globin mRNAs while efficiently recovering the remaining RNA so that the expression profile is maintained. To test these two parameters, three initial quantities of RNA isolated from whole blood were processed in triplicate in the high-throughput GLOBINclear protocol. RNA recovery from the GLOBINclear processing was measured by absorbance at 260 nm. As summarized in Table 1 , R80% of input RNA was recovered in all samples after globin mRNA reduction.
To quantify the levels of aand b-globin mRNA, 5 mL of both the processed RNA and the original, unprocessed RNA were used in qRT-PCR reactions targeting a-globin, b-globin, and hRPII mRNA. Both a-globin and b-globin amplification showed significant shifts after processing by the GLOBINclear globin reduction method; however hRPII remained unaffected by processing (data not shown). a-Globin and b-globin mRNAs were reduced by O94% and O98%, respectively, with various total RNA input ( Table 2 ). Coefficient of Variance (CV) was %6% in all cases, except for b-globin mRNA reduction in the 0.98 mg sample (CV ¼ 14.5%).
The high efficiency of globin mRNA removal, coupled with good RNA recovery, demonstrates that the Mag-MAX-96 Blood protocol followed by GLOBINclear processing provides an effective method for preparing RNA suitable for successful mRNA amplification, labeling, and expression profiling on a microarray.
mRNA Amplification and Expression Profiling on Microarrays
The ultimate test of the quality of the isolated RNA and the effectiveness of globin mRNA removal is the quality of the microarray data after mRNA amplification/labeling. The MessageAmp II-96 aRNA Amplification Kit was used to amplify and label RNA on a Biomek Liquid Handler. 8e10 Each aRNA (15 mg) was then hybridized to GeneChip Human Genome U133 Plus 2.0 Arrays. On average, samples which had not been processed with the GLOBINclear Kit had 17,052 Present calls, while 19,023 (w2000 or w12% more) genes were called Present in samples which had undergone global mRNA reduction. This is consistent with what is observed when the GLOBINclear protocol is carried out manually in a single tube. 16 
CONCLUSION
We have developed a fully streamlined sample preparation workflow for whole blood samples for mRNA expression profiling on a microarray. The use of magnetic bead-based technology in each step enables high-throughput processing and simplifies the robotic setup for automation. With this semi-automated workflow, we were able to obtain high-quality total RNA from whole blood, effectively remove globin mRNAs, and successfully amplify the mRNA, resulting in high-quality microarray data, and 400 samples can be processed in an 8-h work day. With a more sophisticated robot, the entire workflow could be fully automated, enabling robust expression analysis with microarray technology in a high-throughput format. Three input quantities of total RNA were processed in triplicate in the high-throughput GLOBINcleardHuman protocol. RNA was quantified using a NanoDrop Spectrophotometer.
